Universal Time: 21:53  |  Local Time: 21:53 (0h GMT)
Select your timezone:
Room: E-Poster Hall

P-2.20 Anti-rejection therapy does not eliminate donor-reactive IFN-γ and IL-21 producing cells

Nicole M. van Besouw, Netherlands

Internal Medicine - Nephrology & Transplantation
Erasmus MC


Anti-rejection therapy does not eliminate donor-reactive IFN-γ and IL-21 producing cells

Nicole M. van Besouw1, Derek Reijerkerk1, Aleixandra Mendoza Rojas1, Marian C. Clahsen-van Groningen2, Dennis A. Hesselink1, Carla C. Baan1.

1Internal Medicine - Nephrology & Transplantation, Erasmus MC, Rotterdam, Netherlands; 2Pathology, Erasmus MC, Rotterdam, Netherlands

Introduction: IFN-γ and IL-21 have pro-inflammatory properties and support induction and expansion of aggressive cytotoxic T cells. IL-21 also regulates the differentiation of B cells into antibody producing plasma cells, and high numbers are associated with the occurrence of rejection. We investigated whether successful anti-rejection treatment eliminates circulating donor-reactive cytokine producing cells (pc).
Material and Methods: PBMC samples of 85 stable kidney transplant recipients of whom 30 patients were successfully treated with rejection therapy (high-dose corticosteroids for 3 consecutive days (n=23) followed by ATG treatment (n=7) at median 7 days after transplantation, range: 6-48) were analysed by IFN-γ and IL-21 Elispot after rejection treatment (1.22±0.91 years after transplantation). Patient’s PBMC were stimulated with irradiated donor cells or third-party cells that were completely HLA mismatched.
Results: Significantly higher frequencies of donor-reactive IFN-γ and IL-21 pc were found in patients treated with rejection therapy compared to those without rejection [IFN-γ: median 24/3x10E5 PBMC (6-119) vs. 9/3x10E5 PBMC (3-27), p=0.01; IL-21: 27/3x10E5 PBMC (10-59) vs. 9/3x10E5 PBMC (4-32), p=0.004]. No difference was found between the patient groups after third-party stimulation. Remarkably, the number of donor-reactive IFN-γ and IL-21 pc in the rejection treated group was comparable with the third-party reactivity, while the number of donor-reactive cytokine pc in patients without rejection was significantly lower than the third-party reactivity [IFN-γ: 9/3x10E5 PBMC (3-27) vs. 33/3x10E5 PBMC (15-117), p<0.0001; IL-21: 9/3x10E5 PBMC (4-32) vs. 40/3x10E5 PBMC (19-88)  p<0.0001].
Conclusion: High numbers of donor-reactive IFN-γ and IL-21 pc in patients subsequently and successfully treated with anti-rejection therapy appear to be insensitive to therapy. These patients should be more carefully monitored as they are at risk for rejection when their immunosuppressive adherence decreases.


There are no comments yet...

WebApp Sponsor

© 2024 TTS 2020